Exploring the role of EZH2 in RNA editing related to prostate cancer
A novel role for EZH2 in A-to-I RNA editing in prostate cancer
This study is looking at how a protein called EZH2 affects RNA in prostate cancer, with the hope of finding new ways to improve treatment for patients with advanced disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11026357 on NIH RePORTER |
What this research studies
This research investigates how the EZH2 protein, which is known to modify DNA, also influences RNA editing in prostate cancer. By understanding the role of EZH2 in altering RNA, the study aims to identify new therapeutic targets that could improve treatment outcomes for patients with advanced prostate cancer. The approach includes analyzing the expression levels of EZH2 and its impact on RNA stability and mutations, which could lead to better strategies for managing the disease. Patients may benefit from insights that could lead to more effective treatments based on their specific cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have shown resistance to current therapies.
Not a fit: Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve survival rates for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic modifications in cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Cao, Qi — Northwestern University at Chicago
- Study coordinator: Cao, Qi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.